AFFISE
10.5.2021 11:02:10 CEST | Business Wire | Press release
Affise launched a new type of attribution chain technology to measure mobile advertising attribution without the previously required user device identifier for advertisers (IDFA). The removal of the IDFA results from Apple’s App Tracking Transparency (ATT) roll-out.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005320/en/
Initially expected in summer 2020 and later moved to 2021, the iOS14.5 release introduced the ATT policy, which from the moment of roll-out requires every app to get explicit permission from users to access their IDFA. In practical terms, requiring user opt-in eliminates the large part of data vital for end-user identification. Attribution platforms can no longer store and pass user information to an advertiser and back.
These terms leave advertisers with an insufficient amount of data to measure campaign performance and evaluate the efficiency of mobile ads. This could likely affect the efficiency of targeted ads and further decrease the revenue of app publishers.
To alleviate the impact and allow attribution and ad measurement, Apple introduced SKAdNetwork, a privacy-friendly method to measure mobile campaigns’ attribution on iOS apps. The other alternative supported by most MMPs is probabilistic attribution, which relies on the statistics and probability distribution of all the campaigns likely to have generated an install.
Affise announces privacy-enabled attribution chain to support redirects data transfer
Dmitrii Zotov, CTO of Affise, said: “The future of mobile attribution on iOS became the most debated issue and we got actively involved in implementing timely solutions that would allow advertisers and ad networks to attribute app installs. So far, we support both probabilistic attribution from all the MMPs and SKAdNetwork integration. Further, we want to ensure that conversion data will not be lost in a chain of attribution between publishers. Thus we release the privacy-enabled attribution chain, which helps determine conversion along the chain of publishers.”
Apple’s ATT policy may have severe implications on the whole industry, but user privacy is everything nowadays and we should expect major changes around this trend. Meanwhile, advertisers still need to measure conversions, work with traffic suppliers and correctly assign payouts, especially when working with multiple publishers in the chain. By losing the ability to correlate click and conversion, we also lose the ability to relay any past performance data to the publisher.
With MMPs’ restrictions to transfer data only at the source and sub-source level, Affise developed a solution that will support all redirect data transfer. The Affise attribution chain solution uses a particular format of integration macros to pass all the publisher’s data in a simple format.
The attribution chain method protects users’ privacy while ensuring a fair and accurate attribution process for advertising market players.
The macros include all the information needed by the network to determine campaign and traffic source. This means that multiple publishers in the attribution chain will have access to conversion data and will be able to successfully optimize their traffic, where advertisers can ensure the effectiveness of their performance campaigns.
About Affise
Affise is a partnership marketing platform for brands, advertisers and agencies to automate and scale their partner relations via all possible performance marketing channels: traditional affiliates, influencers, networks and agencies. The synergy of technology and the long standing experience allows Affise’s clients to make partnerships manageable and revenue predictable marketing channel. To learn more, visit www.affise.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
